热门资讯> 正文
Avidity Biosciences启动5亿美元拟议公开募股
2025-09-11 04:06
- Avidity Biosciences (NASDAQ:RNA) intends to offer and sell $500.0 million of shares of its common stock in an underwritten public offering.
- Avidity intends to use the net proceeds from this offering, together with its existing cash, cash equivalents and marketable securities, to advance the development of its three late-stage clinical programs, to build appropriate commercial inventory levels to support multiple potential launches, to expand its commercial infrastructure, to progress research and development associated with its AOC platform, and for working capital and general corporate purposes.
- RNA -13.77% after hours to $40.0.
- Source: Press Release
More on Avidity Biosciences
- Avidity Biosciences jumps on report of Novartis takeover approach
- Avidity gets FDA breakthrough therapy status for DMD treatment
推荐文章
风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。
